{"entity":{"id":"cbx-663","kind":"drug","name":"CBX-663","aka":[],"tldr":"CBX-663 is an experimental TCR-mimetic T cell engager from Crossbow Therapeutics, in phase 1 trials for relapsed or refractory myeloid malignancies, advanced solid tumours and recurrent or progressive glioblastoma.","summary":"CBX-663 is a TCR-mimetic T cell engager (T-Bolt) from Crossbow Therapeutics. A first-in-class T cell engager that binds TERT-derived peptide-HLA complexes on tumour cells and activates T cells through a CD3-binding arm. Given into a vein. Its furthest stage is phase 1, for relapsed or refractory myeloid malignancies (AML, MDS, CMML), advanced solid tumours and recurrent or progressive glioblastoma. ClinicalTrials.gov registers it in one study linked below. TelOscope-001 phase 1 NCT07779798 recruiting; first participant dosed per release of 9 September 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Crossbow Therapeutics: crossbowtx.com","url":"https://www.crossbowtx.com/press-release-09-09-26"},{"label":"Crossbow Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT07779798"},{"label":"ClinicalTrials.gov: trials of CBX-663","url":"https://clinicaltrials.gov/search?intr=CBX-663"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["leukaemia","metastatic-cancer","glioblastoma"],"sections":[],"technologies":[],"targets":["tert","cd3"],"drugs":[],"companies":["crossbow-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07779798"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CBX-663","modality":"TCR-mimetic T cell engager (T-Bolt)","mechanism":"A first-in-class T cell engager that binds TERT-derived peptide-HLA complexes on tumour cells and activates T cells through a CD3-binding arm. Given into a vein.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cbx-663/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"tert","kind":"target","name":"TERT","route":"/targets/tert/"}],"company":[{"id":"crossbow-therapeutics","kind":"company","name":"Crossbow Therapeutics","route":"/companies/crossbow-therapeutics/"}],"trial":[{"id":"nct07779798","kind":"trial","name":"A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.","route":"/trials/nct07779798/"}]}}